Okay, let's tackle this question about the proto-oncogene associated with Familial Medullary Thyroid Carcinoma. First, I need to recall the genetic basis of this condition. Familial Medullary Thyroid Carcinoma is part of the Multiple Endocrine Neoplasia type 2 (MEN 2) syndromes. MEN 2 includes MEN 2A, MEN 2B, and Familial Medullary Thyroid Carcinoma (FMTC). The key gene involved here is the RET proto-oncogene.

Wait, the question is asking specifically about FMTC. So, the RET gene is the one responsible.RET is a receptor tyrosine kinase, and mutations in this gene are found in about 95% of FMTC cases. The proto-oncogene becomes an oncogene when mutated, leading to uncontrolled cell proliferation in the medullary thyroid cells.

Now, looking at possible distractors. Common proto-oncogenes like RAS, MYC, or BCL-2 might be options. RAS is involved in other cancers, like colorectal. MYC is associated with lymphomas and some leukemias. BCL-2 is more related to apoptosis regulation, especially in follicular lymphomas. Another possibility is the APC gene, but that's a tumor suppressor involved in familial adenomatous polyposis.

So, the correct answer is RET. The clinical pearl here is that MEN 2 syndromes are all linked to RET mutations, and genetic testing for RET is crucial for early detection and management in families with a history of these conditions. Students should remember that RET is the key gene here, not the other common proto-oncogenes.

**Core Concept**
Familial Medullary Thyroid Carcinoma (FMTC) is caused by germline mutations in the **RET proto-oncogene**, a receptor tyrosine kinase. This gene is central to the pathogenesis of Multiple Endocrine Neoplasia type 2 (MEN 2) syndromes.

**Why the Correct Answer is Right**
The **RET** proto-oncogene encodes a receptor tyrosine kinase critical for cell survival and differentiation in neural crest-derived tissues. In FMTC, gain-of-function mutations in RET lead to constitutive activation of downstream signaling pathways (e.g., MAPK/ERK), driving uncontrolled proliferation of C-cells in the thyroid. Over 95% of FMTC cases and all MEN 2 variants (MEN 2A, MEN 2B) are linked to RET mutations.

**Why Each Wrong Option is Incorrect**
**Option A:** *RAS* is a proto-oncogene involved in various cancers (e.g., pancreatic, colorectal) but not FMTC.
**Option B:** *MYC* overexpression is associated with aggressive lymphomas and some solid tumors, not thyroid carcinomas.
**Option C:** *BCL-2* is a apoptosis regulator implicated in follicular lymphoma, not medullary thyroid cancer.

**Clinical Pearl / High-Yield Fact**
Remember **"RET for RET"** in MEN 2 and FMTC. Genetic screening for RET mutations is essential for early diagnosis and prophylactic thyroidectomy in at-risk families. Distinguish from other thyroid cancers (e.g

✓ Correct Answer: C. RET